Finally, a suboptimal dose (1 × 106 cells per mouse) of these CD19-CAR-T cells expressing the PD-1H targeted shRNA (PD-1H–shRNA–CD19–CAR-T cells) were used to treat NCG mice bearing CD19+ CA-46 lymphoma. This evidence concerns the gene CD19 and lymphoma.